RT Journal Article SR Electronic T1 â–¼Moclobemide for depression JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 6 OP 8 DO 10.1136/dtb.1994.3216 VO 32 IS 1 YR 1994 UL http://dtb.bmj.com/content/32/1/6.abstract AB Relevant BNF section: 4.3.2Moclobemide (Manerix - Roche), the first of a new class of antidepressant drugs, was launched in the UK last year. It is a reversible inhibitor of monoamine oxidase A, which the manufacturer claims is a "first line treatment for major depression". Is this claim justified?